Retour à la liste des essais cliniquesLymphoma

CA-4948-101

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.

Ouvert à Saint-Cloud depuis le : 22/03/2024
Public cible : Adult
Phase : Phase II

Description de l'essai

To determine the safety and tolerability, dose-limiting substances (TLD), maximum tolerated dose (MTD), and recommended phase 2 dose (DRP2) of CA-4948 administered orally as monotherapy and in combination with ibrutinib.

Url of the trial

Investigateur principal

CAROLE SOUSSAIN

Médecin

Contacter